Dabrafenib+Trametinib

DRUG3 trials

Sponsors

Helsinki University Central Hospital, Novartis Pharmaceuticals, Sun Yat-sen University

Conditions

Advanced CancerHaematological MalignancyLung Cancer Stage IIIMetastatic MelanomaMutationSolid Tumor

Phase 2

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

RecruitingNCT05159245

Helsinki University Central HospitalAdvanced Cancer, Haematological Malignancy, Solid Tumor

Start: 2021-12-10End: 2026-11-25Target: 250Updated: 2024-07-15

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

RecruitingNCT06563999

Sun Yat-sen UniversityLung Cancer Stage III, Mutation

Start: 2024-11-01End: 2029-11-01Target: 120Updated: 2024-12-10

Unknown Phase

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

CompletedNCT05611229

Novartis PharmaceuticalsMetastatic Melanoma

Start: 2020-06-16End: 2021-12-03Updated: 2023-04-06

Related Papers

IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results

Acta Oncologica2024-05-238 citations

ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial

BMC Cancer2023-02-2223 citations